The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
Takuto HaraJunya FurukawaYasuyoshi OkamuraYukari BandoTomoaki TerakawaKen-Ichi HaradaSatoru TakahashiYuzo NakanoMasato FujisawaPublished in: International journal of urology : official journal of the Japanese Urological Association (2023)
RPI was a poor prognostic factor in advanced urothelial carcinoma treated with pembrolizumab, possibly resulting in a poorer prognosis for UTUC compared with BC.